Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Michele MerliSara RattottiMichele SpinaFrancesca ReMarina MottaFrancesco A PiazzaLorella OrsucciAndrés José Maria FerreriOmar PerbelliniAnna DoderoDaniele VallisaAlessandro PulsoniArmando SantoroPaolo SacchiValentina ZuccaroEmanuela ChimientiFilomena RussoChiara RusconiAnna Linda ZignegoLuigi MarcheselliFrancesco PassamontiStefano LuminariMarco PaulliRaffaele BrunoLuca Arcaininull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
HCV eradication by DAAs was achieved in 100% of HCV-positive patients with indolent lymphomas not requiring immediate conventional treatment and resulted in non-negligible rate of lymphoma responses. Treatment with DAAs should be considered as the first-line therapy in this setting.